Satraplatin

Generic Name: Satraplatin

Drug Type: Small Molecule

Chemical Formula: C_₁₀H_₂₂Cl_₂N_₂O_₄Pt

CAS Number: 129580-63-8

Unique Ingredient Identifier: 8D7B37T28G

Background: Satraplatin is a platinum compound that is currently under investigation as one treatment of patients with advanced prostate cancer who have failed previous chemotherapy. As an investigation drug, it has not yet received U.S. Food and Drug Administration (FDA) approval and is not available in retail pharmacies.

Indication: Investigated for use/treatment in lung cancer, prostate cancer, and solid tumors.

Clinical Trials

Utilizing A Genomic Sig for "BRCAness" to Eval the Efficacy of Satraplatin in Men With Met. Castration Resistant Prostate Ca

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Drug: Satraplatin

First Posted Date: 2011-02-03

Last Posted Date: 2018-02-13

Lead Sponsor: William K. Oh

Target Recruit Count: 13

Registration Number: NCT01289067

Locations: 🇺🇸
Mount Sinai Medical Center, New York, New York, United States

Satraplatin in Children and Young Adults With Refractory Solid Tumors Including Brain Tumors

Phase 1

Completed

Conditions: Solid Tumors
Brain Metastases
Brain Tumors

Interventions: Drug: Satraplatin

First Posted Date: 2010-12-14

Last Posted Date: 2018-07-05

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 9

Registration Number: NCT01259479

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Satraplatin and Vinorelbine in Advanced Solid Tumors

Phase 1

Conditions: Advanced Solid Tumors

Interventions: Drug: Satraplatin in combo with vinorelbine

First Posted Date: 2010-10-13

Last Posted Date: 2010-10-13

Lead Sponsor: Southern Europe New Drug Organization

Target Recruit Count: 27

Registration Number: NCT01220284

Locations: 🇨🇭
Kantonspital Graubünden, Chur, Switzerland
🇨🇭
Istituto Oncologico della Svizzera Italiana - Ospedale San Giovanni, Bellinzona, Switzerland

Satraplatin and Prednisone to Treat Prostate Cancer

Phase 2

Completed

Conditions: Prostate Cancer
Genetic Polymorphism

Interventions: Drug: Satraplatin
Drug: prednisone

First Posted Date: 2008-03-13

Last Posted Date: 2018-10-02

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 24

Registration Number: NCT00634647

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
🇺🇸
Associates in Oncology and Hematology, Rockville, Maryland, United States

Satraplatin and Bevacizumab in Treating Patients With Metastatic Prostate Cancer Previously Treated With Docetaxel

Not Applicable

Completed

Conditions: Prostate Cancer

Interventions: Biological: bevacizumab
Drug: satraplatin

First Posted Date: 2007-07-11

Last Posted Date: 2018-06-12

Lead Sponsor: Barbara Ann Karmanos Cancer Institute

Target Recruit Count: 31

Registration Number: NCT00499694

Locations: 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸
Veterans Affairs Medical Center - Detroit, Detroit, Michigan, United States

A Phase I Trial of Satraplatin Plus Radiation Therapy for Prostate Cancer Patients With Biochemical Recurrence

Phase 1

Terminated

Conditions: Prostate Cancer

First Posted Date: 2007-05-31

Last Posted Date: 2012-03-23

Lead Sponsor: Agennix

Registration Number: NCT00480623

Locations: 🇺🇸
Medical College of Wisconsin, Milwaukee, Wisconsin, United States
🇺🇸
University of California San Francisco, San Francisco, California, United States
🇺🇸
UT Southwestern Medical Center at Dallas, Dallas, Texas, United States

and more 1 locations

Phase I Study of the Combination of Satraplatin and Abraxane in Advanced Cancers

Phase 1

Completed

Conditions: Advanced Cancers

Interventions: Drug: Satraplatin
Drug: Abraxane

First Posted Date: 2007-05-15

Last Posted Date: 2013-01-23

Lead Sponsor: Yale University

Target Recruit Count: 15

Registration Number: NCT00473720

Locations: 🇺🇸
Yale University, Comprehensive Cancer Center, New Haven, Connecticut, United States

Expanded Access Study of Satraplatin Plus Prednisone in Patients With Hormone Refractory Prostate Cancer (HRPC)

Phase 3

Terminated

Conditions: Prostate Cancer

Interventions: Drug: Oral Satraplatin

First Posted Date: 2007-03-22

Last Posted Date: 2012-08-17

Lead Sponsor: Agennix

Target Recruit Count: 344

Registration Number: NCT00450970

Locations: 🇺🇸
Mid-Ohio Oncology/Hematology, Columbus, Ohio, United States
🇺🇸
Lone Star Oncology Consultants, Austin, Texas, United States
🇺🇸
Virginia Oncology Associates, Newport News, Virginia, United States

and more 116 locations

A Study Comparing Sequential Satraplatin & Erlotinib to Erlotinib in Unresectable Stage 3/4 Non-small-cell Lung Cancer (NSCLC)

Phase 2

Completed

Conditions: Lung Cancer

Interventions: Drug: Erlotinib
Drug: Satraplatin

First Posted Date: 2006-08-31

Last Posted Date: 2012-08-07

Lead Sponsor: Agennix

Target Recruit Count: 100

Registration Number: NCT00370383

Locations: 🇺🇸
Highlands Oncology Group, Bentonville, Ohio, United States
🇺🇸
Signal Point Hematology/Oncology, Middleton, Ohio, United States
🇨🇦
Princess Margaret Hospital, Toronto, Canada

and more 13 locations

Study of Satraplatin With Capecitabine to Treat Advanced Solid Malignancies

Phase 1

Terminated

Conditions: Malignancies

First Posted Date: 2006-05-24

Last Posted Date: 2012-03-23

Lead Sponsor: Agennix

Target Recruit Count: 24

Registration Number: NCT00329329

Locations: 🇺🇸
Northwestern University Medical Center, Chicago, Illinois, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy